BR112012004701A2 - compostos e composições para tratamento do câncer - Google Patents
compostos e composições para tratamento do câncerInfo
- Publication number
- BR112012004701A2 BR112012004701A2 BR112012004701A BR112012004701A BR112012004701A2 BR 112012004701 A2 BR112012004701 A2 BR 112012004701A2 BR 112012004701 A BR112012004701 A BR 112012004701A BR 112012004701 A BR112012004701 A BR 112012004701A BR 112012004701 A2 BR112012004701 A2 BR 112012004701A2
- Authority
- BR
- Brazil
- Prior art keywords
- compositions
- cancer treatment
- treatment compounds
- compounds
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/86—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27575409P | 2009-09-02 | 2009-09-02 | |
| PCT/US2010/047615 WO2011028860A2 (fr) | 2009-09-02 | 2010-09-02 | Composés et compositions pour le traitement du cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012004701A2 true BR112012004701A2 (pt) | 2018-06-12 |
Family
ID=43625764
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012004701A BR112012004701A2 (pt) | 2009-09-02 | 2010-09-02 | compostos e composições para tratamento do câncer |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP2473506A4 (fr) |
| JP (1) | JP2013503888A (fr) |
| KR (1) | KR20120104165A (fr) |
| CN (1) | CN102625805A (fr) |
| AU (1) | AU2010289493A1 (fr) |
| BR (1) | BR112012004701A2 (fr) |
| CA (1) | CA2772614A1 (fr) |
| IN (1) | IN2012DN01878A (fr) |
| WO (1) | WO2011028860A2 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101629642B1 (ko) | 2014-06-25 | 2016-06-13 | 서울대학교산학협력단 | 피퍼롱구민을 유효성분으로 함유하는 지방간 예방용 식품 조성물, 지방간 치료용 약학 조성물, 지방간 치료용 동물 의약품 및 사료 조성물 |
| GB201715008D0 (en) * | 2017-09-18 | 2017-11-01 | Inst De Medicina Molecular Faculdade De Medicina Univ De Lisboa | TRPV2 Antagonists |
| KR20200081633A (ko) | 2018-12-27 | 2020-07-08 | 주식회사 티에스디라이프사이언스 | 피퍼롱구민을 함유하는 담도폐쇄증 치료 또는 예방용 의약 조성물 |
| CN110002987B (zh) * | 2019-03-22 | 2020-09-15 | 南通大学 | 苯基亚烯丙基环己烯酮衍生物及制备方法和用途 |
| CN117229205A (zh) * | 2023-09-14 | 2023-12-15 | 中国医学科学院基础医学研究所 | 苯基丙烯酰胺类rhbdd1抑制剂制备方法及制药用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2478901A3 (fr) * | 2007-02-14 | 2012-11-14 | Mars Incorporated | Composés neurogènes |
| US20100093613A1 (en) * | 2007-03-09 | 2010-04-15 | Kunkel Eric J | Methods for identifying agents and their use for the prevention or stabilization of fibrosis |
| CN102146054A (zh) | 2010-02-10 | 2011-08-10 | 新昌县来益科技开发有限公司 | 荜茇酰胺衍生物及其药物组合物和在制备抑制肿瘤生长的药物中的用途 |
-
2010
- 2010-09-02 BR BR112012004701A patent/BR112012004701A2/pt not_active IP Right Cessation
- 2010-09-02 AU AU2010289493A patent/AU2010289493A1/en not_active Abandoned
- 2010-09-02 EP EP10814469A patent/EP2473506A4/fr not_active Withdrawn
- 2010-09-02 CN CN2010800418987A patent/CN102625805A/zh active Pending
- 2010-09-02 JP JP2012528029A patent/JP2013503888A/ja active Pending
- 2010-09-02 WO PCT/US2010/047615 patent/WO2011028860A2/fr active Application Filing
- 2010-09-02 CA CA2772614A patent/CA2772614A1/fr not_active Abandoned
- 2010-09-02 IN IN1878DEN2012 patent/IN2012DN01878A/en unknown
- 2010-09-02 KR KR1020127007113A patent/KR20120104165A/ko not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011028860A3 (fr) | 2011-07-21 |
| AU2010289493A1 (en) | 2012-04-19 |
| KR20120104165A (ko) | 2012-09-20 |
| CA2772614A1 (fr) | 2011-03-10 |
| EP2473506A2 (fr) | 2012-07-11 |
| CN102625805A (zh) | 2012-08-01 |
| WO2011028860A2 (fr) | 2011-03-10 |
| IN2012DN01878A (fr) | 2015-08-21 |
| JP2013503888A (ja) | 2013-02-04 |
| EP2473506A4 (fr) | 2013-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1007972A2 (pt) | composições de combinação e métodos para o tratamento de câncer | |
| BRPI0919238A2 (pt) | métodos e composições para o tratamento de câncer | |
| BR112012004979A2 (pt) | composições para o tratamento de semente e métodos | |
| BRPI1008566A8 (pt) | métodos e composições para o diagnóstico e tratamento de câncer | |
| BRPI1011587A2 (pt) | compostos e composições terapèuticas | |
| BR112012018947A2 (pt) | composição farmacêutica para tratamento e\ou prevenção do cancêr | |
| BRPI1008564A2 (pt) | métodos e composições para o dignóstico e tratamento de câncer | |
| BR112012005594A2 (pt) | tratamento de câncer | |
| BRPI0908854A2 (pt) | composições e métodos para o tratamento de tumor de origem hematopoética | |
| BRPI1010874A8 (pt) | composição para o tratamento de câncer de próstata | |
| BRPI0909164A2 (pt) | método e composições para o tratamento de câncer | |
| BR112012001604A2 (pt) | composição para cuidado pessoal | |
| DK2121139T3 (da) | Formulations for cancer treatment | |
| BRPI1013618A2 (pt) | pirimidinas substituídas para o tratamento de câncer | |
| BR112012004281A2 (pt) | uso de metformina tratamento e prevenção de câncer | |
| BRPI1011325A2 (pt) | composições e métodos para o tratamento de inflamação | |
| BRPI0911112A2 (pt) | composições e métodos para o tratamento do câncer de mama | |
| SMT201700056B (it) | Fosfaplatine e relativo utilizzo per il trattamento di cancro | |
| BR112012002269A2 (pt) | implemento para tratar superfície | |
| DK3443957T3 (da) | Forbindelser og sammensætninger til behandling af cancer | |
| BRPI0813670A2 (pt) | Compostos para tratamento | |
| BRPI1007600A2 (pt) | composições e métodos para tratamento de doenças cardiovasculares | |
| ITTO20110641A1 (it) | Composizioni farmaceutiche e metodi di trattamento | |
| BRPI0922884A2 (pt) | compostos para tratamento de câncer | |
| BR112012004080A2 (pt) | composições farmacêuticas para tratar ibd |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application fees: application dismissed [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2476 DE 19-06-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |